Hochman Cole Investment Advisors Inc. boosted its stake in Pfizer Inc. (NYSE:PFE) by 4.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 10,376 shares of the biopharmaceutical company’s stock after purchasing an additional 396 shares during the period. Hochman Cole Investment Advisors Inc.’s holdings in Pfizer were worth $381,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of PFE. Corbett Road Capital Management LLC purchased a new position in Pfizer in the 2nd quarter valued at approximately $25,000. Reitz Capital Advisors LLC purchased a new stake in shares of Pfizer during the 2nd quarter worth $29,000. Rocky Mountain Advisers LLC lifted its position in shares of Pfizer by 847.5% during the 2nd quarter. Rocky Mountain Advisers LLC now owns 1,118 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 1,000 shares during the last quarter. JJJ Advisors Inc. purchased a new stake in shares of Pfizer during the 2nd quarter worth $44,000. Finally, Lenox Wealth Management Inc. lifted its position in shares of Pfizer by 22.5% during the 2nd quarter. Lenox Wealth Management Inc. now owns 2,029 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 372 shares during the last quarter. Hedge funds and other institutional investors own 69.08% of the company’s stock.

In other news, Director Ronald E. Blaylock purchased 13,000 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were acquired at an average cost of $38.55 per share, for a total transaction of $501,150.00. Following the completion of the purchase, the director now directly owns 4,000 shares in the company, valued at approximately $154,200. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.08% of the company’s stock.

NYSE PFE traded up $0.75 during trading on Friday, reaching $38.18. The company’s stock had a trading volume of 28,992,325 shares, compared to its average volume of 20,809,482. Pfizer Inc. has a twelve month low of $27.88 and a twelve month high of $40.97. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.42. The business’s fifty day moving average price is $36.59 and its 200-day moving average price is $36.49. The firm has a market cap of $212.16 billion, a price-to-earnings ratio of 15.15, a P/E/G ratio of 3.10 and a beta of 0.66.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.14. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The business had revenue of $11.80 billion for the quarter, compared to analyst estimates of $11.55 billion. During the same period in the previous year, the business posted $0.80 earnings per share. The business’s revenue was down 11.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.84 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, November 6th will be paid a dividend of $0.38 per share. The ex-dividend date is Thursday, November 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 3.98%. Pfizer’s dividend payout ratio (DPR) is 51.53%.

Several equities research analysts have recently issued reports on the stock. ValuEngine cut shares of Pfizer from a “hold” rating to a “sell” rating in a research report on Thursday, July 30th. Truist assumed coverage on shares of Pfizer in a research report on Friday. They set a “buy” rating and a $42.00 price objective for the company. Berenberg Bank assumed coverage on shares of Pfizer in a research report on Tuesday, September 29th. They set a “hold” rating and a $38.00 price objective for the company. Mizuho reaffirmed a “buy” rating and set a $43.00 price objective on shares of Pfizer in a research report on Tuesday, September 15th. Finally, Morgan Stanley lifted their price target on shares of Pfizer from $36.00 to $42.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $39.81.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: How is net asset value different from market price?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.